To understand the frequency of lung and brain tumor sub-types that are NAPRT negative and therefore represent patients likely to benefit from the niacin + NAMPT inhibitor combination, several commercially available tumor microarrays were stained with the 3C6D2 antibody and the proportion of cells within each sample scored for NAPRT expression. This evidence concerns the gene NAPRT and brain neoplasm.